Brief: SynAct Pharma Q1 Sales SEK 0
27/05/2025 06:30
May 27 (Reuters) - SynAct Pharma Q1 adjusted EPS SEK -0.51. Q1 operating expenses SEK 28.098 million Q1 cash flow from operating activities SEK -28.826 million Q1 net income SEK -24.684 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026